Tepmetko® (tepotinib) – New drug approval
February 3, 2021 - EMD Serono announced the FDA approval of Tepmetko (tepotinib), for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
Download PDF
